.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Mallinckrodt
Boehringer Ingelheim
US Army
Accenture
QuintilesIMS
Cerilliant
Fish and Richardson
Colorcon
US Department of Justice

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,034,366

« Back to Dashboard

Which drugs does patent 8,034,366 protect, and when does it expire?


Patent 8,034,366 protects OZURDEX and is included in one NDA.

This patent has fifty-seven patent family members in twenty-four countries.

Summary for Patent: 8,034,366

Title:Ocular implant made by a double extrusion process
Abstract: The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.
Inventor(s): Shiah; Jane-Guo (Irvine, CA), Bhagat; Rahul (Irvine, CA), Blanda; Wendy M. (Tustin, CA), Nivaggioli; Thierry (Los Altos, CA), Peng; Lin (Palo Alto, CA), Chou; David (Palo Alto, CA), Weber; David A. (Danville, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:11/932,101
Patent Claim Types:
see list of patent claims
Use; Compound; Device; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Allergan
OZURDEX
dexamethasone
IMPLANT;INTRAVITREAL022315-001Jun 17, 2009RXYesYes8,034,366► SubscribeY TREATMENT OF MACULAR EDEMA
Allergan
OZURDEX
dexamethasone
IMPLANT;INTRAVITREAL022315-001Jun 17, 2009RXYesYes8,034,366► SubscribeY TREATMENT OF UVEITIS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,034,366

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,506,987Ocular implant made by a double extrusion process► Subscribe
9,192,511Ocular implant made by a double extrusion process► Subscribe
8,034,370Ocular implant made by a double extrusion process► Subscribe
8,778,381Ocular implant made by a double extrusion process► Subscribe
8,318,070Ocular implant made by a double extrusion process► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,034,366

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI332846► Subscribe
Taiwan200621263► Subscribe
Slovenia1776091► Subscribe
Russian Federation2389479► Subscribe
Russian Federation2007103318► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Argus Health
Medtronic
Citi
Boehringer Ingelheim
Colorcon
Express Scripts
UBS
Healthtrust
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot